Cash Payments Made Related to Equity Investments

No definition available.

Name:	gild_CashPaymentsMadeRelatedToEquityInvestments
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Collaboration Arrangement, License Oral Integrase Inhibitors, Option Period

+ References

No definition available.

+ Details

Name:	gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod
Namespace Prefix:	gild_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Collaboration Arrangement, Net Product Sales Threshold

+ References

No definition available.

+ Details

Name:	gild_CollaborationArrangementNetProductSalesThreshold
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Collaboration Arrangement, Percent Of Global Development And Commercialization Costs

+ References

No definition available.

+ Details

Name:	gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts
Namespace Prefix:	gild_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Collaboration Arrangement, Percent Of Global Product Revenues

+ References

No definition available.

+ Details

Name:	gild_CollaborationArrangementPercentOfGlobalProductRevenues
Namespace Prefix:	gild_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Equity Securities, FV-NI, Maximum Percentage Of Outstanding Stock Allowed To Be Purchased

+ References

No definition available.

+ Details

Name:	gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased
Namespace Prefix:	gild_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Equity Securities, FV-NI, Purchase Period

+ References

No definition available.

+ Details

Name:	gild_EquitySecuritiesFVNIPurchasePeriod
Namespace Prefix:	gild_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Equity Securities, FV-NI, Restriction Period

+ References

No definition available.

+ Details

Name:	gild_EquitySecuritiesFVNIRestrictionPeriod
Namespace Prefix:	gild_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Equity Securities, FV-NI, Shares

+ References

No definition available.

+ Details

Name:	gild_EquitySecuritiesFVNIShares
Namespace Prefix:	gild_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Equity Securities, FV-NI, Shares Acquired

+ References

No definition available.

+ Details

Name:	gild_EquitySecuritiesFVNISharesAcquired
Namespace Prefix:	gild_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Payments To Acquire Equity Securities, FV, NI

+ References

No definition available.

+ Details

Name:	gild_PaymentsToAcquireEquitySecuritiesFVNI
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Upfront Collaboration Expenses Related to Other Collaborative Arrangements

+ References

No definition available.

+ Details

Name:	gild_UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.

+ References

No definition available.

+ Details

Name:	us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_VariableInterestEntityLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=gild_MerckMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=gild_OralFormulationProductMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=gild_InjectableFormulationProductMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=gild_ArcusStockPurchaseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_OwnershipAxis=gild_ArcusBiosciencesIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=gild_OtherCollaborationArrangementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_ArcusBiosciencesIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=gild_CommonStockPurchaseAgreementAndInvestorRightsAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

COLLABORATIONS AND OTHER ARRANGEMENTS (Details) - USD ($) shares in Millions			3 Months Ended		12 Months Ended
	Mar. 13, 2021	May 27, 2020	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Merck Sharp & Dohme Corp agreement
Collaborative Arrangements
Percent of global development and commercialization costs	60.00%
Option period to license	5 years
Merck Sharp & Dohme Corp agreement \| Merck
Collaborative Arrangements
Percent of global development and commercialization costs	40.00%
Merck Sharp & Dohme Corp agreement \| Oral Formulation Product
Collaborative Arrangements
Net product sales threshold	$ 2,000,000,000.0
Percent of global product revenues	65.00%
Merck Sharp & Dohme Corp agreement \| Injectable Formulation Product
Collaborative Arrangements
Net product sales threshold	$ 3,500,000,000
Percent of global product revenues	65.00%
Arcus stock purchase agreement \| Arcus
Collaborative Arrangements
Ownership percentage by noncontrolling owners			19.50%
Other collaboration arrangements
Collaborative Arrangements
Upfront collaboration expenses related to other collaborative arrangements			$ 62,000,000	$ 97,000,000
Cash payments made related to equity investments			$ 59,000,000	$ 8,000,000
Arcus \| Arcus stock purchase agreement
Collaborative Arrangements
Equity securities acquired (in shares)			5.7		8.2
Payments to acquire equity securities			$ 220,000,000		$ 261,000,000
Equity securities (in shares)			13.8
Purchase period		5 years
Restriction period		3 years
Arcus \| the “Stock Purchase Agreements”
Collaborative Arrangements
Maximum percentage of outstanding stock allowed to be purchased		35.00%